Progesterone antagonists

Inventors

Nickisch, Klaus • Cessac, James • Narkunan, Kesavaram • Das, Baishakhi

Assignees

Evestra Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-8673968-B2

Patent

Publication Date

2014-03-18

Expiration Date


Abstract

Described herein are compounds which exhibit progesterone antagonistic effects and methods of treating cancer using such compounds.

Core Innovation

The patent describes a class of progesterone antagonists defined as progesterone-antagonist steroid structures according to formula (I) and formula (II), with variable substituents including R1 through R6 and/or R5. The steroid framework includes stereochemical α/β orientation, and the compounds are characterized by specified structural features, including examples designated as 1a through 1f with aryl/heteroaryl substitutions.

The compounds of formula (II) include a substituent selection in which R5 is defined as a particular heteroaryl group, including -3-furanyl and, in some embodiments, -3-pyridyl. The disclosure further describes multiple possible substituent options for R5 in the general progesterone-antagonist steroid family, together with the corresponding stereochemical framework. Pharmaceutically acceptable salts and progesterone-antagonist steroid compositions are also addressed.

The patent links the structural class to progesterone receptor antagonism for cancer therapy. Experimental evaluation of agonist/antagonist behavior is provided using cell-based progesterone receptor and glucocorticoid receptor reporter assays, including reporter gene system components and specific assay platforms. The disclosed results report progesterone antagonism with inhibition IC50 values relative to RU-486 and note minimal glucocorticoid antagonism for the tested examples.

Claims Coverage

The provided set includes two independent claims. The inventive coverage is concentrated on a specific chemical compound defined by formula (II) with R5 being -3-furanyl, and a pharmaceutical composition comprising inert carriers and a formula (II) compound where R5 is -3-furanyl or -3-pyridyl.

Formula (II) compound with -3-furanyl at R5

A compound of formula (II) where R5 is -3-furanyl.

Pharmaceutical composition with formula (II) compound and inert carriers

A pharmaceutical composition comprising one or more pharmacologically inert carriers and a compound of formula (II) where R5 is -3-furanyl or -3-pyridyl.

Across the independent claims, the core inventive subject matter is a formula (II) progesterone-antagonist steroid compound defined by the R5 substituent identity (-3-furanyl, and additionally -3-pyridyl for the composition claim), optionally formulated with pharmacologically inert carriers.

Stated Advantages

Progesterone antagonism is reported, with inhibition IC50 values relative to RU-486.

Minimal glucocorticoid antagonism is noted for the tested examples.

Documented Applications

Cancer therapy application is described in connection with progesterone receptor antagonism of the disclosed progesterone-antagonist steroid compounds.

Use of cell-based progesterone receptor and glucocorticoid receptor reporter assays is documented for evaluating agonist/antagonist behavior and receptor activity results.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.